Ciclopirox oral - BioTheryX

Drug Profile

Ciclopirox oral - BioTheryX

Alternative Names: BTX-10504; Ciclopirox olamine

Latest Information Update: 29 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioTheryX
  • Developer BioTheryX; The Leukemia & Lymphoma Society; University Health Network
  • Class Antifungals; Pyridones; Small molecules
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 29 Apr 2016 No recent reports on development identified - Phase-I for Acute myeloid leukaemia, Multiple myeloma and Myelodysplastic syndromes (Second-line therapy or greater) in Canada (PO)
  • 02 Dec 2010 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top